HD2A RASC-Research and Evaluation Core

研究和评估核心：项目摘要/摘要 虽然有效的初级预防、减少危害、治疗和恢复支持干预措施 物质使用障碍和疼痛是存在的，但它们并不广泛存在。横向传播和 实施(D&I)需要科学的方法来选择和交付有效和高效的方法 在不同背景下的实施策略。研究采用支持中心的研究和 评价(R&E)核心，与行政、药物使用障碍执行支助协调 (SUD-IS)和Pain实施支持(Pain-IS)核心，利用集成、多学科、迭代的 提供快速评估、专家技术援助并推动长期采用和 维持循证干预措施。R&E核心的总体目标是提升D&I HD2A创新项目的能力和翻译的长期影响。我们通过以下途径实现这一点 标准化的基准信息和对数据、分析和研究翻译需求的按需支持， 所有这些都是为了通过以科学为基础的融资和政策来利用可持续的变化。我们将提供州政府- 指导下，在D&I测量、框架、建模和测试/评估方面的ART方法学支持 由R&E核心专家在HHS的四个支柱上进行了广泛的工作。与其他人保持一致 RASC核心，我们由3个动态阶段指导：1)通过3)评估创新项目的基线D&I能力 方法；2)协助创新项目提高研发能力，同时支持统一数据 跨项目的收集和报告；以及，3)促进创新项目的可持续性和潜力 放大，并作为HD2A建模和经济的D&I研究方法论资源 资源中心(MERC)和数据基础设施支持中心(DISC)。R&E核心的一个关键功能是 形成性评价，这是一项阶段性评价，将纳入在HD2A内部和整个HD2A中吸取的经验教训 受赠人，具有形成性的评估报告(第1年、第3年)，重点是提供洞察力，以支持及时决策- 受资助者和美国国立卫生研究院所作的修改和路线修正，以及一份侧重于告知未来的最终报告(第5年) 这类倡议。我们还将进行5个快速扭亏为盈的研究项目，旨在生产 解决HD2a确定的长期或新出现的执行或维持障碍的知识 受赠人。第一年的项目将侧重于保险覆盖范围和其他融资的作用 以及广泛采用阿片类药物使用障碍(MOUD)的报销障碍。 在HD2A计划内和之外，我们大胆地寻求为成瘾提供知识和方法 以及疼痛干预领域，其最终目标是实现转型和公平的公共卫生利益。

RESEARCH AND EVALUATION CORE: PROJECT SUMMARY/ABSTRACT Although effective primary prevention, harm reduction, treatment, and recovery support interventions for substance use disorders and pain exist, they are not widely available. Crosscutting dissemination and implementation (D&I) scientific methods are required to select and deliver effective and efficient implementation strategies under variable contexts. The Research Adoption Support Center’s Research and Evaluation (R&E) Core, in concert with the Administrative, Substance Use Disorder Implementation Support (SUD-IS) and Pain Implementation Support (Pain-IS) cores, utilizes an integrated, multidisciplinary, iterative approach to provide rapid assessment, expert technical assistance, and advance the long-term adoption and sustainment of evidence-based interventions. The overarching goal of the R&E Core is to elevate the D&I capability and translational long-term impact of the HD2A Innovation Projects. We achieve this via standardized baseline information and on-demand support for data, analytic, and research translation needs, all toward leveraging sustainable change through science-based financing and policies. We will provide state- of-the art methodological support in D&I measurement, frameworks, modeling, and testing/evaluation, guided by R&E Core experts who have conducted extensive work across the four HHS pillars. Aligned with other RASC cores, we are guided by 3 dynamic phases: 1) ASSESS Innovation Projects’ baseline D&I capacity via 3 methods; 2) ASSIST the Innovation Projects in increasing D&I capability, while supporting harmonized data collection and reporting across projects; and, 3) ADVANCE Innovation Projects’ potential for sustainment and scale-up, and serve as the D&I research methodology resource to the HD2A Modeling and Economic Resource Center (MERC) and Data Infrastructure Support Center (DISC). A key function of the R&E core is the formative evaluation, a phased evaluation that will incorporate lessons learned within and across HD2A grantees, with formative evaluation reports (Years 1, 3) focused on providing insight to support timely decision- making and course corrections by grantees and NIH, and a final report (Year 5) focused on informing future initiatives of this kind. We also will conduct 5 Rapid Turnaround Research Projects designed to produce knowledge to address persistent or emerging barriers to implementation or sustainment identified by HD2A grantees. The Year 1 project will focus on the role of insurance coverage and other financing and reimbursement barriers to the widespread adoption of medications for opioid use disorder (MOUD). Within and beyond the HD2A program, we boldly seek to contribute knowledge and methods to the addiction and pain intervention fields with the ultimate goal of transformational and equitable public health benefit.